LSE:HVO (hVIVO Plc)
About HVO
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
hVIVO Plc (LSE: HVO) Latest News

Investing Articles
“My best-performing UK stock in 2023 has been…”

Investing Articles
This ex-penny stock just paid its first ever dividend. Here’s how much

Investing Articles
This ex-penny stock is up 111% in 6 weeks. Should I buy more?

Investing Articles
Best British small-cap stocks to buy for February

Investing Articles
3 no-brainer UK shares to buy in February

Investing Articles
1 penny stock I’m buying right now!
